Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um Estudo para Avaliar a Eficácia da IDCT (Terapia Celular Intradiscal) em Indivíduos com Doença Discal Degenerativa Lombar Sintomática Ligeira a Moderada de Um Nível (IDCT)

14 de outubro de 2026 atualizado por: DiscGenics, Inc.

Um Estudo Prospectivo, Randomizado, Duplamente Cego, Controlado por Simulação, Multicêntrico para Avaliar a Segurança e Eficácia do IDCT em Indivíduos com Degeneração Discal Intervertebral Lombar Sintomática Ligeira a Moderada de Nível Único

This is a Phase III, randomized, double-blinded, Sham-controlled, multi-center study in subjects with single-level, symptomatic lumbar (L3- S1) intervertebral disc degeneration. The study will have a 52-week primary period followed by 52 week Follow-up Period (total of 104 weeks).

The study protocol will be approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC), and the study will be conducted in accordance with Good Clinical Practice (GCP). All subjects will provide written informed consent prior to Screening.

Approximately 162 subjects will be enrolled in the study. Up to 45 days prior to treatment, subjects will be screened for study inclusion, which includes obtaining baseline MRI and X-ray imaging. Imaging results for subjects initially eligible for study participation will be sent to a central imaging vendor for review and confirmation of eligibility, including the number of levels with degeneration. Subjects meeting all inclusion/exclusion criteria will be assigned to the corresponding treatment arm group and subsequently randomized to IDCT or Sham.

Randomization will occur approximately 7 to 14 days prior to the scheduled treatment administration date.

Overall, 162 subjects will be enrolled and randomized to IDCT or Sham in a 2:1 ratio.

  • IDCT (n=108)
  • Sham (n=54)

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

Adult subjects with a diagnosis of single-level, mild to moderate, symptomatic lumbar (L3-S1) intervertebral disc degeneration that give consent and meet all the inclusion criteria and none of the exclusion criteria will be enrolled in this study. The disease, single-level disc will be known as the 'target disc' and will be either L3/L4, L4/L5, or L5/S1.

Tipo de estudo

Intervencional

Inscrição (Estimado)

162

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

  • Estados Unidos
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35235
        • Recrutamento
        • Alabama Clinical Therapeutics
        • Investigador principal:
          • Brad 205-833-2228, MD
        • Contato:
    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85054
        • Recrutamento
        • Mayo Clinic (AZ)
        • Investigador principal:
          • John Freeman, MD
        • Contato:
      • Scottsdale, Arizona, Estados Unidos, 85251
        • Recrutamento
        • HonorHealth
        • Investigador principal:
          • Luis Tumialan, MD
        • Contato:
    • Arkansas
      • Little Rock, Arkansas, Estados Unidos, 72205
        • Recrutamento
        • University of Arkansas for Medical Sciences
        • Contato:
        • Investigador principal:
          • Erica Petersen, MD
    • California
      • San Diego, California, Estados Unidos, 92111
        • Recrutamento
        • Solaris Research Institute
        • Investigador principal:
          • Krishnan Chakravarthy, MD
        • Contato:
      • Santa Monica, California, Estados Unidos, 90403
        • Recrutamento
        • Source Healthcare
        • Investigador principal:
          • Timothy Davis, MD
        • Contato:
      • Thousand Oaks, California, Estados Unidos, 91320
        • Recrutamento
        • Pain Management and Injury Relief
        • Contato:
        • Investigador principal:
          • Alexander Hersel, MD
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20006
        • Recrutamento
        • International Spine, Pain and Performance Center
        • Investigador principal:
          • Mehul Desai, MD
        • Contato:
    • Florida
      • Jacksonville, Florida, Estados Unidos, 32224
        • Recrutamento
        • Mayo Clinic (FL)
        • Contato:
        • Investigador principal:
          • Wenchun Qu, MD
      • Miami, Florida, Estados Unidos, 33136
        • Recrutamento
        • University of Miami Health System
        • Contato:
        • Investigador principal:
          • Barth Green, MD
      • Orlando, Florida, Estados Unidos, 32832
      • St. Petersburg, Florida, Estados Unidos, 33709
        • Recrutamento
        • Vantage Clinical Trials
        • Investigador principal:
          • Robert Guirguis, MD
        • Contato:
      • Tampa, Florida, Estados Unidos, 33709
        • Recrutamento
        • Vantage Clinical Trials
        • Investigador principal:
          • Jorge Leal, MD
        • Contato:
    • Idaho
      • Boise, Idaho, Estados Unidos, 83709
        • Rescindido
        • Injury Care Family Care Research
      • Post Falls, Idaho, Estados Unidos, 83854
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60612
        • Recrutamento
        • Rush University Medical Center
        • Investigador principal:
          • John O'Toole, MD
        • Contato:
    • Indiana
      • Carmel, Indiana, Estados Unidos, 46032
        • Recrutamento
        • Indiana Spine Group
        • Contato:
        • Investigador principal:
          • Kevin Macadaeg, MD
    • Kentucky
      • Louisville, Kentucky, Estados Unidos, 40202
        • Recrutamento
        • Norton Leatherman Spine Center
        • Contato:
        • Investigador principal:
          • Steven Glassman, MD
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70121
        • Recrutamento
        • Ochsner Health System
        • Investigador principal:
          • Maged Guirguis, MD
        • Contato:
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Recrutamento
        • Mayo Clinic (MN)
        • Investigador principal:
          • Ryan D'Souza, MD
        • Contato:
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63141
        • Recrutamento
        • The Orthopedic Center of St. Louis
        • Contato:
        • Investigador principal:
          • Matthew Gornet, MD
    • New York
      • New York, New York, Estados Unidos, 10022
        • Recrutamento
        • Weill Cornell Medicine for Comprehensive Spine Care
        • Contato:
        • Investigador principal:
          • Prabhav Deo, MD
    • North Carolina
      • Wilmington, North Carolina, Estados Unidos, 28403
        • Recrutamento
        • Wake Research
        • Investigador principal:
          • Jeremy Hoff, MD
        • Contato:
      • Winston-Salem, North Carolina, Estados Unidos, 27103
        • Recrutamento
        • Carolinas Pain Institute/ Center For Clinical Research
        • Investigador principal:
          • Christopher Gilmore, MD
        • Contato:
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 10524
        • Recrutamento
        • Cleveland Clinic
        • Contato:
        • Investigador principal:
          • Jijun Xu, MD
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97404
        • Recrutamento
        • Pacific Sports and Spine
        • Investigador principal:
          • Gregory Moore, MD
        • Contato:
    • Pennsylvania
      • King of Prussia, Pennsylvania, Estados Unidos, 19406
        • Recrutamento
        • Main Line Spine
        • Investigador principal:
          • Scott Davidoff, MD
        • Contato:
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38120
        • Recrutamento
        • Semmes Murphey Neurological Clinic
        • Contato:
        • Investigador principal:
          • Michael LaBagnara, MD
        • Contato:
    • Texas
      • Austin, Texas, Estados Unidos, 78745
        • Recrutamento
        • Pain Specialists of America
        • Investigador principal:
          • Genaro Gutierrez, MD
        • Contato:
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84108
        • Recrutamento
        • University of Utah
        • Investigador principal:
          • Zachary McCormick, MD
        • Contato:
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23238
        • Recrutamento
        • Virginia iSpine Physicians
        • Investigador principal:
          • Michael DePalma, MD
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 75 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Has a diagnosis of mild to moderate, symptomatic, single-level degenerative disc disease (DDD) from L3-S1.

  2. Has a target disc that meets Modified Pfirrmann Grade 3-7, as determined by a central radiologist.

  3. Is ≥18 and ≤75 years of age, skeletally mature, and has a body mass index (BMI) ≥18 kg/m2 and ≤38 kg/m2 at Screening.

  4. Has been experiencing chronic low back pain for at least 6 months prior to Screening.

  5. Has had low back pain that is unresponsive to at least 3 months of conservative care (nonoperative treatment) to include at least one non-pharmacological intervention which may include physical therapy, acupuncture, chiropractic manipulation, massage, and at home medically supervised exercise program and two pharmacological interventions which may include NSAIDs, acetaminophen, duloxetine, and/or injectable therapy.

  6. Has pre-treatment low back pain score of 45 to 90 on VAS (Visual Analogue Scale) for low back pain at Screening and Day 1.

  7. Has pre-treatment ODI score of 35 to 90 at Screening and Day 1.

  8. Is willing to voluntarily sign the informed consent form and agrees to the release of previous medical history for purposes of this study (i.e., HIPAA authorization) at Screening.

  9. Is physically and mentally able to comply with the protocol, able to understand and complete the required forms, and willing and able to adhere to the requirements of the protocol in the opinion of the Investigator.

  10. Female-born subjects of childbearing potential must agree to and comply with using highly effective methods of birth control for the duration of the study (e.g., oral contraceptive, implant, injectable, indwelling intrauterine device, sexual abstinence, condoms, or a vasectomized partner).-

    Exclusion Criteria:

    Physical/ Medical History Exclusion Criteria

  11. Has low back pain that in the Investigator's opinion is predominately myofascial in nature.

  12. Has constant, unchanging low back pain that is not improved in any spinal position.

  13. Has radiculopathy resulting from nerve compression.

  14. Has non-radicular unilateral or bilateral leg pain with intensity greater than 50% of the intensity of the low-back pain, as measured by VAS.

  15. Leg pain that is of radicular origin, i.e., due to stimulation of nerve roots or dorsal root ganglion of a spinal nerve by compressive forces.

  16. Has frequent leg pain that extends below the knee.

  17. Has severe unilateral or bilateral osteoarthritis of the knee or hip.

  18. Severe spinal arthritis

  19. Has cauda equina syndrome.

  20. Has had previous lumbar spine surgery.

  21. Has had previous disc invasive treatment procedures (i.e., intradiscal electrothermal therapy, intradiscal radiofrequency thermocoagulation) or intradiscal injections (i.e., injection of corticosteroids, methylene blue, dextrose, or glucosamine and chondroitin sulfate) or diagnostic discography at L3-S1 within the 3 months prior to Screening.

  22. Subjects who have had basivertebral nerve ablation at L3-S1.

  23. Has clinical suspicion of facet pain as the primary pain generator.

  24. Has current infection at the planned procedure site, active systemic infection, or current or prior history of lumbar spinal infection (i.e., discitis, septic arthritis, epidural abscess).

  25. Has a history of fibromyalgia.

  26. Has tested positive for Hepatitis B virus (HBV), Hepatitis C virus (HCV), or Human Immunodeficiency Virus (HIV).

  27. Has presence of an active malignancy or tumor, or a prior history of malignancy within the last five years (except for basal cell carcinoma of the skin).

  28. Has presence or prior history of a spinal malignancy.

  29. Has significant systemic disease, such as unstable angina or autoimmune disease, such as rheumatoid arthritis. Has a history of congenital or acquired coagulopathy or thrombocytopenia.

31. Is currently taking anticoagulant, antiplatelet, or thrombolytic medications (except for aspirin or nonsteroidal anti-inflammatory drugs [NSAIDS]) and at the Investigator's medical discernment and discretion is unable to withhold medications for the time required per site standard or care, prior to the IDCT injection or is taking antineoplastic medications.

32. Is at higher risk for post-surgical infection (e.g., taking immunosuppressants), has a severe infection or a history of serious infection.

33. Has concomitant conditions requiring daily oral steroid usage for more than 30 days in the preceding 90 days before Screening.

34. Is taking opioids greater than 20 MME per day on an intermittent (as needed) basis OR is taking 20 MME or greater daily for more than 3 months prior to Screening

35. Has a history of unexplained, easy, or persistent bruising or bleeding, bleeding from the gums, or bleeding problems experienced in previous surgical procedures.

36. Has a history of hypersensitivity or anaphylactic reaction to bovine products, sodium hyaluronate/ hyaluronan/ hyaluronic acid, gentamicin, amphotericin b, dimethyl sulfoxide (DMSO), crustaceous/ shellfish, or porcine products.

37. Has an uncontrolled psychiatric condition or substance/alcohol abuse that would potentially interfere with the subject's participation in the study within 2 years prior to Screening in the opinion of the Investigator.

38. Has positive serum pregnancy test or nursing at time of Screening or has plans to become pregnant within the planned length of the study (2 years).

39. Has a body habitus that precludes adequate fluoroscopic visualization for the procedure or the procedure is physically impossible.

40. Has or requires an implantable electronic defibrillator, pacemaker, or has other contraindication to MRI scanning or cannot tolerate MRI scanning. Subjects who are expected to require a defibrillator or pacemaker, as determined by the Investigator should be excluded.

41. Has participated in another clinical study within the 6 months prior to Screening.

42. Has been a recipient or plans to be a recipient during trial participation of stem cell product to treat the lumbar spine.

43. Has participated in a prior IDCT clinical study.

44. Has pending litigation against a health care professional, except where required by the insurer as a condition of coverage.

45. A person who would not be available for the entire planned length of the trial.

46. Has active or pending worker's compensation claims. 47. In the Investigators opinion, the subject is not suitable for participation in the clinical trial.

Imaging Exclusion Criteria:

48. Three discs (L3-S1) that have a Modified Pfirrmann Grade 4-7.

49. Has evidence of prior lumbar vertebral body fracture at L3-S1.

50. Has scoliosis with curvature > 10 degrees.

51. Has congenital spinal irregularities such as segmentation.

52. Has an acute fracture of the spine at the time of enrollment in the study. Clinically compromised vertebral bodies within L3-S1 due to current or past trauma, e.g., sustained pathological fracture or multiple fractures of vertebrae.

53. Has evidence of dynamic instability on lumbar flexion extension per screening radiographs as indicated by >4.5 mm of translational motion at L3-S1; >15° of angular motion at L3/-L4; >20° of angular motion at L4-L/5; or >25° angular motion at L5/-S1.

54. Has Grade 2 or higher spondylolisthesis at L3-S1, as assessed by Meyerding classification.

55. Has lumbar spondylitis or other undifferentiated spondyloarthropathy.

56. Has Modic Type III Changes at L3-S1.

57. Has radiographic evidence or suspicion of a full thickness annular tear at L3-S1.

58. Has evidence of abnormal disc morphology defined as an extrusion or sequestration according to Fardon classification at L3- S1.

59. Has herniation > 3 mm in AP dimension that is associated with nerve root compression.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: IDCT (n=108); Intradiscal injection of IDCT in a single target disc

1 mL intradiscal injection of 9,000,000 cells/mL
Biológico: IDCT (rebonuputemcel)

Single intradiscal injection of 1 mL of 9,000,000 cells/mL IDCT in a single target disc.
Comparador Falso: Sham (n=54);

Needle insertion up to the annulus of a single target disc.
Outro: Sham (No Treatment)

Single Sham needle insertion up to the annulus of a single target disc.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Visual Analogue Scale (VAS) for low back pain
Prazo: Week 52

VAS is a sliding visual scale of 0 being "no pain" and 100 being "worst pain Imaginable' to assess changesfrom baseline in low back pain compared to Sham
Week 52
Oswestry Disability Index (ODI)
Prazo: Week 52

ODI is a 10-item questionnaire used to measure functional disability in people with low back pain. It is a self-administered tool that assesses how back pain affects daily activities like walking, sleeping, and personal hygiene, with scores ranging from 0% (no disability) to 100% (maximum disability).
Week 52
Adverse Events
Prazo: Day 1 to Week 52 in each treatment group.

Incidence of grade 2 (moderate) or greater AEs and SAEs
Day 1 to Week 52 in each treatment group.
Adverse events of special interest
Prazo: Day 1 to Week 52 in each treatment group

Incidence of Adverse Events of Special Interest (AESI) to include any symptomatic injury of the target disc including annular tear, disc herniation/extrusion/prolapse as well as discitis.
Day 1 to Week 52 in each treatment group

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Visual Analogue Scale (VAS)
Prazo: Week 4, 12 and 26, 78 and 104

VAS is a sliding visual scale of 0 being "no pain" and 100 being "worst pain Imaginable' to assess changes from baseline in low back pain
Week 4, 12 and 26, 78 and 104
Oswestry Disability Index (ODI)
Prazo: Week 4, 12 and 26, 78 and 105

ODI is a 10-item questionnaire used to measure functional disability in people with low back pain. It is a self-administered tool that assesses how back pain affects daily activities like walking, sleeping, and personal hygiene, with scores ranging from 0% (no disability) to 100% (maximum disability).
Week 4, 12 and 26, 78 and 105
EQ-5D
Prazo: Enrollment through Week 104

EQ-5D is a validated too consisting of a set of questions covering five dimensions, with each dimension having a different severity level.

  1. Mobility: Ranging from "no problems walking about" to "confined to bed". Self-care: Ranging from "no problems with self-care" to "unable to wash or dress myself".
  2. Usual activities: Ranging from "no problems doing my usual activities" to "unable to do my usual activities" (e.g., work, study, housework).
  3. Pain/discomfort: Ranging from "no pain or discomfort" to "extreme pain or discomfort".
  4. Anxiety/depression: Ranging from "not anxious or depressed" to "extremely anxious or depressed".
  5. Visual Analog Scale (EQ VAS): A scale (typically 0-100) where respondents mark their overall health from "worst imaginable" to "best imaginable".
Enrollment through Week 104
Disc Volume
Prazo: Day 1 to Week 104

MRI assessment of Disc Volume though Week 104
Day 1 to Week 104
Pain Medication Use
Prazo: Enrollment to Week 104

Concomitant pain medication use for low back pain related to the target disc
Enrollment to Week 104
Concomitant Therapy
Prazo: Enrollment to Week 104

Concomitant medical therapy for low back pain (physical therapy, acupuncture, chiropractic manipulation, massage, and at-home, medically supervised exercise program etc.) use for low back pain
Enrollment to Week 104
Treatment Failure Rate
Prazo: Enrollment to week 104

Treatment failure rate (defined as an invasive non-surgical or surgical intervention) directly related to the target disc.
Enrollment to week 104
Adverse Events
Prazo: Enrollment to Week 104

The incidence of grade 2 (moderate) or greater AEs and SAEs
Enrollment to Week 104
Adverse Events of Special Interest (AESI)
Prazo: Enrollment to Week 104

The incidence of Adverse Events of Special Interest (AESI) observed defined as any one of the followings symptomatic injury of the target disc including annular tear, disc, herniation/extrusion/prolapse or any case of discitis.
Enrollment to Week 104

Outras medidas de resultado

Medida de resultado
Descrição da medida
Prazo
MRI Based evaluations
Prazo: Enrollment through Week 104

MRI Evaluation of the lumbar spine will be reported as an aggregate in one report to assess of disc height, Modified Pfirrmann grade, Modic changes, annular tears/fissures, endplate integrity, herniation, and any additional noteworthy observations at 12, 26, 52, 78, and 104.
Enrollment through Week 104
X-ray evaluation of the lumbar spine
Prazo: Screening through Week 104

X-ray evaluation of flexion/extension will be assessed and measure in degrees of angles.
Screening through Week 104

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

DiscGenics, Inc.

Investigadores

  • Diretor de estudo: Lisa Flood, DiscGenics, Inc.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

23 de dezembro de 2025

Conclusão Primária (Estimado)

24 de novembro de 2027

Conclusão do estudo (Estimado)

24 de novembro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

17 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de novembro de 2025

Primeira postagem (Real)

28 de novembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

15 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de outubro de 2026

Última verificação

1 de outubro de 2026

Mais Informações

Termos relacionados a este estudo

Palavras-chave

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • DGX-A02

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

INDECISO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever